Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
CNBC Stocks· Aug 5, 2026 · 10:45 AM
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 6 hours ago
Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
Investing.com
stocksabout 6 hours ago
Morgan Stanley private credit fund redemption requests remain elevated in third quarter
Investing.com
stocksabout 6 hours ago
Gemini hacked three companies in first known breakout by Google’s AI
Investing.com